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Cyclosporin is largely metabolized by hepatic cytochrome 
P450 enzymes, and azole drugs that inhibit cytochrome 
P450 may precipitate cyclosporin toxicity. The allylamine 
terbinafine binds to a small subfraction of hepatic cyto-
chrome P450 in type I fashion, and has no effect upon hepatic 
metabolism of cyclosporin in vitro. The purpose of this study 
was to determine whether oral terbinafine alters the pharma-
cokinetics of oral cyclosporin in vivo. 
Twenty male volunteers (age 19-44 years), were ran-
domly allocated to two groups. The first group received three 
single oral doses of cyclosporin 300 mg at intervals of 21 d. 
The second and third doses of cyclosporin were preceded by a 
6-d course of oral terbinafine 250 mg each morning. A fur-
ther 250 mg of terbinafine was taken with the second and 
third doses of cyclosporin. Blood levels of cyclosporin and 
terbinafine were monitored for 36 h after each dose. The 
second group received a 7 -d course of terbinafine 250 mg 
each morning. On the seventh day a single dose of cyclo-
C yclosporin is a cyclic polypeptide immunosuppres-sive agent extensively used in organ-transplant pa-tients to suppress rejection and graft-versus-host re-actions in bone-marrow transplantation, and is also used to treat a wide range of immune-mediated in-
flammatory conditions [1]. Cyclosporin has a narrow therapeutic 
range, and has potentially serious side effects . The metabolism of 
cyclosporin has been shown to be inhibited by azole anti-fungal 
drugs, both irl villa and in vitro [2 - 9]. Terbinafine is a new allylamine 
class anti-fungal agent used in the treatment of fungal infections of 
the skin and nails, and has been shown inllitro to have no effect upon 
the hepatic metabolism of cyclosporin [10]. Patients on long-term 
immunosuppressive therapy have an increased prevalence of colo-
nization with pathogenic fungi [11] and may require systemic anti-
fungal therapy. The aim of this study was to determine whether oral 
terbinafine alters the pharmacokinetics of oral cyclosporin in vivo, 
and thus if it is likely to be safe to prescribe terbinafine in patients 
receiving concomitant cyclosporin. This was an open, single-
center, three-period crossover study in which the period two regi-
men was repeated in period three. This design was chosen so that 
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sporin 300 mg was taken together with the terbinafine. 
Blood levels of both cyclosporin and terbinafine were moni-
tored for 36 h. Two further single doses of cyclosporin 
300 mg were given at intervals of 2 weeks and the cyclo-
sporin levels again monitored. In both groups each cyclo-
sporin dose was preceded by an 8-h fast. 
The mean peak blood concentration of cyclosporin when 
taken alone was 958 ,ug/l, and 822 when taken with terbina-
fine. The mean area under the curve for cyclosporin was 4207 
,ug/l/h when taken alone and 3665 when taken with terbin-
afine. The mean absorption half- life for cyclosporin when 
taken alone was 0.29 h, and 0.33 when taken with terbina-
fine. The mean time of maximum concentration and elimi-
nation half-life of cyclosporin were unaltered by terbinafine. 
The results suggest that terbinafine is likely to prove a safe 
systemic anti-fungal treatment for patients who are taking 
cyclosporin. Key words: il7Ieractiol7/anli-jungal. ] Invest Derma-
101102:740-743, 1994 
any carry-over effects could be tested against the within-subject 
variability of cyclosporin pharmacokinetics. 
MATERIALS AND METHODS 
Ethical approval was granted by the Joint Ethics Committee of the Univer-
sity of Wales, and the University of Wales College of Medicine. Twenty 
healthy male volunteers ages from 19 to 44 years, (mean 27.2) were re-
cruited. All were screened to exclude physical illness. A detailed medical and 
a drug history was taken, and a full physical examination was performed. 
Samples of blood were taken for a full blood count, liver function tests, and 
measurement of plasma, urea, creatinine, and electrolytes. The subjects had 
not received terbinafine or taken allY drug known to interfere with the 
pharmacokinetics of cyclosporin within the previous three months. The 
subjects were randomly allocated to one of two gronps (sequence 1 or se-
quence 2). The mean height of those randomized to sequence 1 was 177 Col, 
and of those randomized to sequence 2 was also 177 cm; the mean weights 
were 75.9 kg and 78.8 kg, respectively. 
Those allocated to sequence 1 received three single oral doses of cyclo-
sporin300 mg at intervals of21 d. The second and third doses of cyclosporin 
were preceded by a 6-d course of oral terbinafine 250 mg. A further 250 mg 
of terbinafine was taken at the same time as the second and third doses of 
cyclosporin. 
Those allocated to sequence 2 received a 7-d course ofterbinafine 250 mg 
first thing each morning. On the seventh day a single dose of cyclosporin 
300 mg was taken together with the terbinafine. Two further single doses of 
cyclosporin 300 mg were taken at intervals of 14 d. In both groups each dose 
of cyclosporin was preceded by an 8-h fast, and subjects were provided with a 
standard luncheon 3 h following the dose of cyclosporin and a standard 
supper in the evening. The study protocol is summarized in Table I. 
Samples of blood were collected into glass tubes containing ethylene 
diaminetetraacetic acid anti-coagulant at 0 h, immediately prior to each dose 
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Table I. An Outline of the Study Protocol· 
Sequence 1 
Sequence 2 
Period 1 
Cy-----+ 
Cy + T -------+ 
• Cy, cyclosporin; T, terbinafine. 
Period 2 
Cy + T -------+ 
Cy 
Period 3 
Cy+T 
Cy 
of cyclosporin. Further blood samples were taken at 0.5, 0.75,1,1.5,2,2.5, 
3,3.5,4,4.5,5,6,8,10,12,24,28,32, and 36 h. Whole blood collected for 
determination of cyclosporin levels was stored at -20 ·C. Whole blood 
cyclosporin was measu:cd alone and in combination with cyclosporin me-
tabolites usmg, respectively, the Cyclo-Trac SP and Cyclo-Trac NS radlO-
inununoassay kits (INCSstar Corporation, MN). The kits were used accord-
ing to the manufacturer's instructions until the end of incubation, at which 
tUne 500 III of polylethylene glycol in water was added prior to centrifuga-
tion. The calibration standards were prepared using citra ted whole blood. 
The calibration range used was 12.5 to 1600 Ilg/l and 38.6 to 52881lg/1 for 
the specific and non-specific assays, respectively. The calibration data were 
fitted using a four-parameter logistic equation using RIACALC (version 
2.57, Pharmacia, Turku, Finland). 
Each assay batch contained all of the samples of one subject and four levels 
of quality control were measured in each assay batch. For the specific assay 
the nominal concentrations of the four controls were 100, 500, 1000, and 
2000 Ilg/l and the measured coefficient of variation for all was less than 12%. 
The minimum detectable concentration was estimated as 21 and 291lg/1 for 
the specific and the non-specific assays, respectively. 
Samples of whole blood taken for measurement of terbinafine levels were 
first centrifuged at 1000 X g for 10 min, and the plasma was then drawn and 
stored in a glass vial at - 20· C. The plasma concentration of terbinafine and 
its N-demethylated metabolite were measured using a high-performance 
liquid chromatography (HPLe) method. The samples were prepared using 
the standard method [12], and 100 III were injected into the HPLC column. 
Quality control standards received from Sandoz Pharmaceuticals were ana-
lyzed to ensure comparibility of the results. The lower limit of detection was 
2 ng/ml. The coefficients of variation for terbinafine and its demethylated 
metabolite were 4.6% and 7.2%, respectively. 
For each individual (following each 300-mg dose of cyclosporin) the 
maximum plasma concentration (Cmax) of cyclosporin and the time to 
maximum peak concentration (Tmax) were determined. The area under the 
cyclosporin blood concentration/time curve (AUe) from 0 to 36 h was 
calculated by the linear trapezoidal rule. The absorption and elimination 
half-lives were also calculated. The absorption rate for each individual sub-
ject was determined using a regression model for all data points up until the 
Cmax. The slope of the regression line was calculated and from this the 
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absorption rate for that in :lividual according to the formula absmption 
rate = (log 2)/coefficient of the slope. 
A similar calculation was made using poinrs after the Cmax to determine 
the elimination rate for cyclosporin. The Tmax, Cmax, and AUC (follow-
ing the seventh daily dose) were also calculated for terbinafine where appro-
priate. 
The pharmacokinetic data was examined using parametric crossover anal-
ysis that tested for treatment, period, and carry over effects. The data was 
then analyzed by treatment (i.e., cyclosporin alone, and cyclosporin plus 
terbinafine). These data plus the results from the crossover analysis were 
combined so that the rwo one-sided tests procedure could be performed to 
test for bioequivalence berween cyclosporin alone and cydosporin plus ter-
binafine. 
RESVLTS 
Specific Cyclosporin Assay In sequence 1 the mean Tmax for 
cyclosporin was 1.8 h when taken alone, and 1.8 and 1.9 h when 
taken with terbinafine. The mean peak blood concentration of cy-
closporin when taken alone was 885 ,ug/l, and 885 and 772 when 
taken with terbinafine. The mean AVC for cyclosporin (in se-
quence 1) were 3755 ,ug/ljh when cyclosporin was taken alone and 
3810 and 3448 when taken with terbinafine. The absorption half-
lives for cyclosporin were 0.27 h when taken alone, and 0.34 and 
0.32 when taken with terbinafine. The elimination half-lives were 
5.35 h when taken alone, and 5.94, and 6.44 when taken with 
terbinafine. 
In sequence 2 the mean Tmax for cyclosporin was 2.0 h when 
taken with terbinafine and 1.8 and 2.1 when taken alone. The 
Cmax for cyclosporin was 809 ,ug/I when cyclosporin was taken 
with terbinafine, and 979 and 1011 when taken alone. The AVC 
for cyclosporin was 3736,ug/ljh when taken with terbinafine, and 
4591 and 4275 when taken alone. The absorption half-life of cyclo-
sporin was 0.34 h when taken with terbinafine, and 0.28 and 0.31 
when taken alone. The elimination half-life of cyclosporin was 
5.30 h when taken with terbinafine and 5.74 and 5.49 when taken 
alone. The mean Tmax, mean Cmax, mean AVC, mean elimina-
tion half-life, and mean absorption half-life for cyclosporin for both 
sequence 1 and sequence 2 are shown in Table II. 
Terbinafine Assay In sequence 1 the Cmax for terbinafine was 
1500 ng/ml, and 1416 in period 2 and period 3, respectively. The 
Tmax was 1.01 hand 1.3. The AVCs were 6766 ng/ml/h and 
8124. In sequence 2 (period one only) the Cmax for terbinafine was 
1120.0 ng/ml and the Tmax was 1.4 h . The AVC was 6244.2 
Table II. Pharmacokinetic Data for Cyclosporin by Sequence (Specific Assay) 
Sequence 1 Sequence 2 
P Value for 
Treatment Difference 
Tmax (h) 
Period 1 1.81 (1.17-2.45)' 2.00 (1.53-2.47) 
Period 2 1.80 (1.14-2.46) 1.81 (1.15-2.47) NSb 
Period 3 1.91 (1.24 - 2.53) 2.11 (1.58 -2.64) 
Cmax (Ilg/l) 
Period 1 885.0 (686-1084) 808.5 (684-933) 
Period 2 884.6 (747 -1022) 979.1 (780-1178) P = 0.03 
Period 3 771.7 (515-1028) 1011.1 (878 -1144) 
AUC (,ug/l/h) 
Period 1 3755.1 (2868 -4642) 3735.7 (3263-4209) 
Period 2 3810.3 (3241- 4380) 4591.4 (3755-5428) p = 0.05 
Period 3 3447.8 (2608-4288) 4275.2 (3648-4902) 
Absorption tl/2 (h) 
Period 1 0.27 (0.21-0.33) 0.34 (0.23-0.45) 
Period 2 0.34 (0.24-0.44) 0.28 (0.22-0.34) NS 
Period 3 0.32 (0.23-0.41) 0.31 (0.27 -0.35) 
Elimination tl /2 (h) 
Period 1 5.35 (4.88-5.82) 5.30 (4.77 -5.83) 
Period 2 5.94 (5.25-6.63) 5.74 (5.07-6.41) NS 
Period 3 6.44 (5.68-7.20) 5.49 (4.84-6.14) 
• 95% confidence intervals are given in parentheses. 
• NS, not significant. 
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Table III. Pharmacokinetic Data for Terbinafine by Sequence 
Tmax (h) 
Period 1 
Period 2 
Period 3 
Cmax (ng/ml) 
Period 1 
Period 2 
Period 3 
AVC (ng/ml/h) 
Period 1 
Period 2 
Period 3 
Sequence 1 
1.0 (1.02 - 0.99)' 
1.3 (1.7 -1.0) 
1500 (1617-1383) 
1416 (1557-1276) 
6766 (7739-5792) 
8124 (9216-7032) 
• 950/0 confidence intervals arc given in parentheses. 
ng/ml/h. No statistical difference was found between the three 
terbinafine pharmacokinetic profiles. The results of the terbinafine 
assay are summarized in Table III. 
Analysis by Treatment When analyzed by treatment, i.e., cy-
closporin alone or cyclosporin plus terbinafine, the mean Tmax for 
cylosporin was 1.9 h both when taken alone and when taken with 
terbinafine. The mean Cmax of cyclosporin was 958 when taken 
alone, and 822 when taken with terbinafine (a mean decrease of 
14%). The mean AUC for cyclosporin was 4207 ttg/l/h when 
alone and 3665 when taken with terbinafine. The mean absorption 
half-life for cyclosporin was 0.29 h when taken alone and 0.33 h 
when taken with terbinafine. The mean elimination half-life for 
cyclosporin was 5.5 h when taken alone and 5.9 when taken with 
terbinafine. 
Though the Tmax and the elimination half-lives for the two 
treatments were found statistically to be bioequivalent, the Cmax, 
AUC, and absorption half-lives were not. The results of the analysis 
by treatment is shown in Table IV. 
Non-Specific Cyclosporin Assay Statistical analysis of the re-
sults of the cyclosporin levels using the non-specific monoclonal 
assay showed that the Cmax and AUC of cyclosporin were not 
bioequivalent for the two treatments (i.e., cyclosporin alone or cy-
closporin and terbinafine); however the Tmax for both treatments 
were found to be bioequivalent (as they were for the specific assay). 
The results of the non-specific assay are shown in Table V. 
DISCUSSION 
Individuals with impaired cell-mediated immunity are at risk from 
developing both superficial and systemic fungal infections. Shuttle-
worth et af demonstrated an increased prevalence of colonization 
with pathogenic fungi in transplant patients on long-term immun-
osuppresion than normal age- and sex-matched controls [11]. Cy-
closporin is a cyclic polypeptide immunosuppressive agent exten-
sively used in transplant patients to suppress rejection and 
graft-versus-host reactions in bone-marrow transplantation, and 
also to treat a wide range of autoimmune diseases [1]. Cyclosporin is 
largely metabolized by hepatic cytochrome P450 enzymes to form 
its primary hydroxylated and N-demethylatcd metabolites M17, 
Sequence 2 
1.4 (1.8 -1.0) 
1120 (1158-1082) 
6244.2 (7459 - 5029) 
P Value for 
Sequence Difference 
NS 
NS 
NS 
Ml, and M21, which have negligible pharmacologic actiVity. 
Drugs that are metabolized by or which induce hepatic cytochrome 
P450 enzymes may interfere with the metabolism of cyclosporin 
[1]. Cyclosporin has a narrow therapeutic range, and increased 
blood levels of cyclosporin may lead to nephrotoxicity with hyper-
tension and hyperkalaemia. Other side effects include gastrointesti-
nal disturbance, hepatotoxicity, hirsutism, acne, gum hypertrophy, 
and neurotoxicity. Decreased blood levels of cyclosporin in trans-
plant patients may lead to graft rejection, and in patients receiving 
cyclosporin for other indications lower levels may lead to a de-
creased therapeutic effect. 
The metabolism of cyclosporin has been shown to be inhibited by 
azole anti-fungal drugs, both ill vivo and in vitro [2-10]. Azoles 
inhibit a cytochrome P450 enzyme lanosterol 14-demethylase that 
is involved in fungal ergosterol, and hence fungal cell membrane, 
bio-synthesis [13,14], and azoles have also been shown to inhibit 
hepatic cytochrome P-450 III A4, an important enzyme in the me-
tabolism of cyclosporin [15]. The azole drug fluconazole has been 
shown to be less inhibitory of hepatic cyclosporin metabolism ill 
vitro than either ketoconazole or itraconazole, and Kruger et af 
showed no evidence of a significant interaction with cyclosporin in 
bone-marrow-transplant recipients [16]. However clinically im-
portant interactions with cyclosporin have been reported at higher 
doses of fluconazole [5 - 7]. 
Terbinafine is a fungicidal drug of the allylamine class with a 
broad spectrum antifungal activity and is indicated for fungal infec-
tion of the skin and nails caused by Tric/lOphytorl} MicrosporulII sp.} 
and Epidermophyton jloccosum when oral therapy is considered ap-
propriate. Allylamines inhibit fungal squalene epoxidase, a non-
cytochrome P450 enzyme, which is also important in fungal ergos-
terol synthesis [17]. Although terbinafine is metabolized by hepatic 
cytochrome P450 it has only a moderate affinity for one relatively 
small fraction of these enzymes [18 ,19]. In contrast, azoles have a 
high affinity for hepatic cytochrome P450 enzymes [20] . Back and 
Tija demonstrated that terbinafine does not inhibit the metabolism 
of cyclosporin by human liver microsomes in vitro [10]. 
The results of this study support the results of the ill vivo investi-
gations that suggested that terbinafine would not cause an increase 
in the blood concentration of cyclosporin. In fact, however, both 
Table IV. Pharmacokinetic Data for Cyclosporin Analyzed by Treatment 
Tmax (h) 
Cmax (J.Lg/I) 
AVC (J.Lg/l/h) 
Absorption tl / 2 (h) 
Elimination tl/2 (h) 
" 95% confidence int:crval s arc given in parentheses. 
Cyclosporin 
1.90 (1.6 - 2.2)' " 
958.4 (866-1051) 
4207.3 (3788-4627) 
0.29 (0.26-0.32) 
5.5 (5.16-5 .84) 
Cyclosporin 
+ Terbinafine 
1. 9 (1.6 - 2.2) 
821.6 (728-915) 
3664.6 (3334 - 3996) 
0.33 (0.28-0.38) 
5.9 (5.53-6.27) 
Two One-Sided Tests 
for Bioequivalence 
Bioequivalent 
Not bioequivalent 
Not bioequivalent 
Not bioequivalent 
Bioequivalent 
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Table V. Pharmacokinetic Data for Cyclosporin Analyzed by Treatment (Non-Specific Assay) 
Tmax (h) 
Cmax (ugj l) 
AUC (ugj ljh) 
Cyclosporin 
2.44 (2.73 - 2.15)' 
1,468 (1,631-1 ,304) 
10,919.7 (12,157.3-9,682) 
, 95% confidence intervals arc given in parentheses. 
the AVC and the Cmax for cyclosporin were marginally decreased 
by the concomitant administration of terbinafine. The absorption 
half-life of C)~closporin is sli~htly increased, but the Tmax and elim-
ination half lIfe of cyclosponn remal11 unchanged. The results of the 
non-specific cyclosporin assay, which measures the level of cyclo-
sporin as well a~ its metabolites, w~len analyzed fo~ b!oequivalencc 
using the two-sided test for blOeqUlvalence, were sun1lar to that for 
the specific assay in that the Tmax for both were bioequivalent, but 
the Cmax and AVC were not. 
There are three possible explanations for this phenomenon. 
Firstly, it is possible that terbinafine could bc acting as an enzyme 
inducer, increasing the rate of cyclosporin metabolism, but this is 
unlikely based on the pre-clinical data [10]. Alternatively, terbina-
fine could decrease the absorption of cyclosporin by some as-yet-
unexplained mechanism. However, the most likely explanation is 
that the differences observed are due to the wide inter- and intra-
individual variation of cyclosporin absorrtion from the current for-
mulation of Sandimmun. Lindholm et a have found up to twofold 
intraindividual variation and more than threefold interindividual 
variation in the AVC of cyclosporin even when the cyclosporin was 
given under standard conditions on a weight for weight basis [21] . 
We believe that this wide intra- and inter-individual variation in 
cyclosporin absorption explains some of the apparent anomalies 
seen (Table II) . In sequence 1, periods 1 and 2 (respectively, cyclo-
sporin alone, and cyclosporin with terbinifine), the Cmax and AVC 
for cyclosporin are very similar, but not in periods 2 and 3 (both 
cyclosporin with terbinafl11e). In sequence 2 the Cmax and AVC for 
cyclosporin in periods 2 and 3 (both cyclosporin alone) appear 
higher rather than lower in the terbinafine phase (period 1) (cyclo-
sporin with ~erbinafine). How~v~r, thes~ differences (between the 
different penods) were not statistically slgruficant. 
The reduction in the AVC for cyclosporin when taken with 
terbinafine was small, and there was no evidence to suggest that 
terbinafine would increase the blood levels of cyclosporin. Thus 
terbinafine is likely to prove a safe systemic anti-fungal treatment 
fo r: patients who are taking cyclosporin, and the problem of cyclo-
sporin toxicity associated with the use of azoles should be avoided. 
We aregratefill to Satldoz Pharmaceuticals (UK) Ltd. Jar spotlsoritlg the costs oJthis 
study. 
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